Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Quotient showcases ICHM3 exploratory clinical trials at ASCPT

Quotient BioresearchQuotient Clinical, a business unit of Quotient Bioresearch ("Quotient"), will present two significant poster publications at the forthcoming American Society for Clinical Pharmacology and Therapeutics (ASCPT) meeting to be held on March 12th to 17th in Maryland, USA. 

Co-authored with scientists from seven leading pharmaceutical companies; AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer and Takeda, the first publication - Applications of exploratory clinical trials in drug development - review of exploratory trials user group meeting- reviews the proceedings of a user group meeting that discussed the impact of ICHM3 exploratory clinical trials guidance on conventional drug development paradigms. 

The second publication, co-authored with scientists from GlaxoSmithKline and entitled: A microtracer study of GSK962040, a motilin receptor agonist, to support dosing regimens in the critical care setting, describes the application of Quotient's ivMicrotracerTM technology to support the development of an IV drug product for GSK962040 (a selective motilin agonist) for use in the critical care setting. 

Mark Egerton, Managing Director, Quotient Clinical commented: "These publications demonstrate our commitment to collaborating with our customers on innovative and high-quality clinical research. ICHM3 exploratory studies are being applied increasingly within drug development, with a clear goal of improving the processes by which new medicines are developed."

Details of the two publications are: 

Applications of exploratory clinical trials in drug development - review of exploratory trials user group meeting

Poster Session I (Abstract ID 347; Poster ID 12)

Date: Thursday 15th March 2012, at 8.00am
  

A microtracer study of GSK962040, a motilin receptor agonist, to support dosing regimens in the critical care setting

Poster Session II (Abstract ID 445; Poster ID 75)

Date: Friday 16th March 2012, at 8.00am
 

Quotient will be located at exhibition booth #234 at the conference, and senior members of the Quotient team will be attending the meeting. Copies of the posters will be made available at the booth or via download from the Quotient website at http://www.quotientbioresearch.com/publications/posters.


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events